Our first chart of the month for 2026 looks at four of the fastest growing players among orthopedics’ mid-tier companies.
For our purposes, we’re limiting companies to those between $100 million and $200 million in annual revenue while measuring growth between 2020 and our estimated finish for 2025.
Kuros Biosciences has a 5-year CAGR of 94%, growing from just over $5 million in 2020 to an estimated $140 million at the end of 2025. On a sequential basis, the company grew 47% compared to 2024. Direct sales of MagnetOs have surged and driven significant growth.
BONESUPPORT grew from about $20 million in 2020 to $131 million at the end of last year, a CAGR of 46%. The company’s sequential growth versus last year was 32%. The U.S. market has been a strong growth driver for the company.
SI-BONE remains one of the best performing spine companies with a 5-year CAGR of 22%, growing from $73 million in 2020 to $201 million in 2025. Sequentially, the company grew 20% over its prior year performance. The company has drastically increased the size of its active surgeon base.
OrthoPediatrics’ focus on the pediatric market continues to drive significant growth for the company. It generated a CAGR of 22% over the last five years, growing from $71 million to $189 million. The company grew 8% in 2025 over the prior year.
Company Sales Trends 2020 to 2025E
Our first chart of the month for 2026 looks at four of the fastest growing players among orthopedics' mid-tier companies.
For our purposes, we're limiting companies to those between $100 million and $200 million in annual revenue while measuring growth between 2020 and our estimated finish for...
Company Sales Trends 2020 to 2025E
Our first chart of the month for 2026 looks at four of the fastest growing players among orthopedics’ mid-tier companies.
For our purposes, we’re limiting companies to those between $100 million and $200 million in annual revenue while measuring growth between 2020 and our estimated finish for 2025.
Kuros Biosciences has a 5-year CAGR of 94%, growing from just over $5 million in 2020 to an estimated $140 million at the end of 2025. On a sequential basis, the company grew 47% compared to 2024. Direct sales of MagnetOs have surged and driven significant growth.
BONESUPPORT grew from about $20 million in 2020 to $131 million at the end of last year, a CAGR of 46%. The company’s sequential growth versus last year was 32%. The U.S. market has been a strong growth driver for the company.
SI-BONE remains one of the best performing spine companies with a 5-year CAGR of 22%, growing from $73 million in 2020 to $201 million in 2025. Sequentially, the company grew 20% over its prior year performance. The company has drastically increased the size of its active surgeon base.
OrthoPediatrics’ focus on the pediatric market continues to drive significant growth for the company. It generated a CAGR of 22% over the last five years, growing from $71 million to $189 million. The company grew 8% in 2025 over the prior year.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
